Roche Holding AG (XSWX:ROP) Dividends Received


XSWX:ROP Roche Holding AG XSWX:ROP
76 GF Score
Price CHF339.50
GF Value CHF264.65
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XSWX:ROP
76GF Score
Roche Holding AG XSWX:ROP
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF339.50 is trading 28.3% above its estimated GF Value™ of CHF264.65. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:ROP:

  • Dividends Received:
  • GF Value™: CHF264.65 vs. price of CHF339.50 (28.3% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
76GF Score

Get the complete analysis for XSWX:ROP

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF339.50
Price
CHF264.65
GF Value